Literature DB >> 27959299

Drug-Induced Liver Injury.

Leslie A Hamilton1, Angela Collins-Yoder1, Rachel E Collins1.   

Abstract

Drug-induced liver injury (DILI) can result from both idiosyncratic and intrinsic mechanisms. This article discusses the clinical impact of DILI from a broad range of medications as well as herbal and dietary supplements. Risk factors for idiosyncratic DILI (IDILI) are the result of multiple host, environmental, and compound factors. Some triggers of IDILI often seen in critical care include antibiotics, antiepileptic medications, statins, novel anticoagulants, proton pump inhibitors, inhaled anesthetics, nonsteroidal anti-inflammatory agents, methotrexate, sulfasalazine, and azathioprine. The mechanism of IDILI due to these medications varies, and the resulting damage can be cholestatic, hepatocellular, or mixed. The primary treatment of IDILI is to discontinue the causative agent. DILI due to acetaminophen is intrinsic because the liver damage is predictably aligned with the dose ingested. Acute acetaminophen ingestion can be treated with activated charcoal or N-acetylcysteine. Future areas of research include identification of mitochondrial stress biomarkers and of the patients at highest risk for DILI. ©2016 American Association of Critical-Care Nurses.

Entities:  

Keywords:  adverse drug reactions; clinical practice guidelines; drug-induced liver injury; herbal and dietary supplements

Mesh:

Substances:

Year:  2016        PMID: 27959299     DOI: 10.4037/aacnacc2016953

Source DB:  PubMed          Journal:  AACN Adv Crit Care        ISSN: 1559-7768


  8 in total

Review 1.  Mitochondrial stress response in drug-induced liver injury.

Authors:  Jing Zheng; Qiulin Yuan; Cao Zhou; Weifeng Huang; Xiang Yu
Journal:  Mol Biol Rep       Date:  2021-08-25       Impact factor: 2.316

2.  MiR-122-5p knockdown protects against APAP-mediated liver injury through up-regulating NDRG3.

Authors:  Zhi Yang; Weigang Wu; Pengcheng Ou; Minna Wu; Furong Zeng; Boping Zhou; Shipin Wu
Journal:  Mol Cell Biochem       Date:  2020-11-28       Impact factor: 3.396

3.  Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan.

Authors:  Shih-Wei Lai; Cheng-Li Lin; Kuan-Fu Liao
Journal:  Front Pharmacol       Date:  2017-10-23       Impact factor: 5.810

4.  Drug-Induced Liver Injury Module for Medical Students.

Authors:  Christen K Dilly; Hannah J Craven; Jean P Molleston
Journal:  MedEdPORTAL       Date:  2020-07-15

Review 5.  Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives.

Authors:  Lucija Kuna; Ivana Bozic; Tomislav Kizivat; Kristina Bojanic; Margareta Mrso; Edgar Kralj; Robert Smolic; George Y Wu; Martina Smolic
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

6.  A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC Type 2 Patients.

Authors:  Vanessa Baier; Henrik Cordes; Christoph Thiel; José V Castell; Ulf P Neumann; Lars M Blank; Lars Kuepfer
Journal:  Front Physiol       Date:  2019-09-27       Impact factor: 4.566

7.  Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms.

Authors:  Payal Rana; Michael D Aleo; Xuerong Wen; Stephen Kogut
Journal:  Acta Pharm Sin B       Date:  2021-06-07       Impact factor: 11.413

Review 8.  Drug Toxicity Evaluation Based on Organ-on-a-chip Technology: A Review.

Authors:  Ye Cong; Xiahe Han; Youping Wang; Zongzheng Chen; Yao Lu; Tingjiao Liu; Zhengzhi Wu; Yu Jin; Yong Luo; Xiuli Zhang
Journal:  Micromachines (Basel)       Date:  2020-04-03       Impact factor: 2.891

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.